Back

sST2 adds to the prognostic value of Gal-3 and BNP in chronic heart failure, independent of Mineralocorticoid Receptor Antagonists treatment.

26 May 2018 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 2 - Chronic Heart Failure – Epidemiology, Prognosis, Outcome Epidemiology, Prognosis, Outcome HFA Premium Access Heart Failure 2018

About the speaker

Photo
Doctor Philippe Rouet

Rangueil Hospital of Toulouse, Toulouse (France)

30 More presentations in this session

Presentation thumbnail
Association between resting heart rate, rhythm status and outcomes in patients with heart failure
Doctor Y. Chia (Singapore, SG)
Abstract Slides
Presentation thumbnail
Long-term and clinical profile of patients with heart failure with recovered ejection fraction followed in a non-tertiary hospital heart failure unit.
Mr V. Martinez Mateo (Alcazar de San Juan, ES)
Abstract Slides
Presentation thumbnail
Gender differences in the characteristics and outcomes of heart failure: the israel heart failure disease management study (IHF-DMS)
Professor A. Grupper (Beer Yakov, IL)
Abstract Slides
Presentation thumbnail
Repeated echocardiography in chronic heart failure patients for personalized risk assessment
Doctor O. Manintveld (Rotterdam, NL)
Abstract Slides
Presentation thumbnail
Impact of a structured follow-up in a HF clinic after a HF hospitalization: a propensity score analysis
Doctor E. Cabrera Romero (Murcia, ES)
Abstract

Access the full session

Session thumbnail
Poster Session 2 - Chronic Heart Failure – Epidemiology, Prognosis, Outcome

The Event

Event poster

Heart Failure 2018

26 May - 29 May 2018

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources